Molecular Diagnostics Group

The Competence Network for Innovations in Precision Medicine

The Molecular Diagnostics Group (MDG) is the competence network of the biotechnological and pharmaceutical companies Biotype GmbH, ROTOP Pharmaka GmbH, and qualitype GmbH. These three high-tech companies combine their strengths within the MDG to develop customized, low-side-effect, and cost-effective diagnostic and therapeutic solutions for precision medicine and to promote their broad applicability.

Current Challenges

Advancements in healthcare are progressing rapidly. Over the past few decades, the average life expectancy has increased by approximately 20 years. However, with aging comes a rise in complex diseases such as cancer, posing significant challenges to society. The World Health Organization (WHO) predicts a 77 percent increase in diagnosed cancer cases by 2050.

Therefore, early and precise diagnoses followed by effective and targeted therapies are crucial. The approach of Interceptive Medicine holds great potential, with its core principles focused on the early detection of disease risks, targeted intervention through personalized treatment strategies and prevention, and the effective use of digital technologies, including AI. However, making this widely available in routine healthcare remains complex and costly. The Molecular Diagnostics Group aims to change this with innovative developments.

Our Solutions

Together, our approximately 300 highly specialized employees work on innovative developments in precision medicine to make its groundbreaking applications accessible to as many patients as possible.

Specifically, our efforts focus on three key areas. First, we aim for maximum efficiency in molecular diagnostics. To achieve this, BIOTYPE has developed the MODAPLEX system, a laboratory device for the automated multi-gene analysis of molecular biomarker signatures. Second, ROTOP Pharmaka pursue precise theranostics with radioisotopes, combining imaging diagnostics at the molecular level of a tumor with targeted therapy for those specific tumor cells. Third, qualitype focuses on consistent digitalization and data integration in healthcare.

You can learn more about our solutions in the accompanying video (to enable English subtitles, click the subtitle icon located at the bottom right corner) or read our latest press release.

You are currently viewing a placeholder content from Default. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information
For privacy reasons YouTube needs your permission to be loaded. For more details, please see our Data Protection.
I Accept

(Please select english subtitles.)

Management

Dr. Wilhelm Zörgiebel
Dr. Wilhelm ZörgiebelCEO
MDG
+49 351 8838 200
Rico Wünsche
Rico WünscheCFO
MDG
+49 351 8838 200
Dr. Timm Zörgiebel
Dr. Timm ZörgiebelCEO
BIOTYPE / qualitype
+49 351 8838 2800